124340-96-1

Basic information

• Product Name: 2-(4-DIMETHYLAMINO-PHENYL)-3H-BENZOIMIDAZOLE-4-CARBOXYLIC ACID
• Synonyms: 2-(4-DIMETHYLAMINO-PHENYL)-3H-BENZOIMIDAZOLE-4-CARBOXYLIC ACID;2-(4-(DiMethylaMino)phenyl)-1H-benzo[d]iMidazole-7-carboxylic acid;2-[4-(dimethylamino)phenyl]-1H-1,3-benzodiazole-7-carboxylic acid
• CAS NO: 124340-96-1
• Molecular Formula: C₁₆H₁₅N₃O₂
• Molecular Weight: 281.31
• Mol File: 124340-96-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 562.2°Cat760mmHg
• Flash Point: 293.8°C
• Appearance: /
• Density: 1.333g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.711
• CAS DataBase Reference: 2-(4-DIMETHYLAMINO-PHENYL)-3H-BENZOIMIDAZOLE-4-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-DIMETHYLAMINO-PHENYL)-3H-BENZOIMIDAZOLE-4-CARBOXYLIC ACID(124340-96-1)
• EPA Substance Registry System: 2-(4-DIMETHYLAMINO-PHENYL)-3H-BENZOIMIDAZOLE-4-CARBOXYLIC ACID(124340-96-1)

Safety Data

• Hazardous Substances Data: 124340-96-1(Hazardous Substances Data)

Usage

General Description

The chemical 2-(4-dimethylamino-phenyl)-3H-benzoimidazole-4-carboxylic acid is a compound with a complex and specific structure. It contains a benzoimidazole ring with a carboxylic acid group attached at the 4th position and a 2-(4-dimethylamino-phenyl) group attached at the 2nd position. 2-(4-DIMETHYLAMINO-PHENYL)-3H-BENZOIMIDAZOLE-4-CARBOXYLIC ACID has potential pharmaceutical applications due to its unique structure and properties. It may be used as a building block in the synthesis of various organic and medicinal compounds. Additionally, it may have biological activities that make it relevant for research and development in the field of medicinal chemistry and drug discovery.

InChI:InChI=1/C16H15N3O2/c1-19(2)11-8-6-10(7-9-11)15-17-13-5-3-4-12(16(20)21)14(13)18-15/h3-9H,1-2H3,(H,17,18)(H,20,21)

Upstream product

• 100-10-7 4-dimethylamino-benzaldehyde 
• 603-81-6 2,3-diaminobenzoic acid 
• 124341-05-5 2-Azidocarbonyl-3-nitro-benzoic acid ethyl ester 
• 136285-66-0 3-nitro-phthalic acid-1-ethyl ester-2-chloride 
• 16533-45-2 ethyl 2-carboxy-3-nitrobenzoate 
• 61063-11-4 2-Amino-3-nitrobenzoic acid,ethyl ester 
• 77326-45-5 2-carbamoyl-3-nitrobenzoic acid 
• 606-18-8 3-nitroanthranilic acid 

Relevant articles and documents

Benzimidazole-4-Carboxamide Derivatives, Their Preparation Methods, Pharmaceutical Compositions And Their Uses

The present invention relates to the benzimidazole-4-carboxamide derivatives, their preparation methods, pharmaceutical compositions and their uses; wherein X represents monosubstituted or bissubstituted or polysubstitued C1-C14 alkoxy, monosubstituted or bisubstituted or polysubstitued C1-C14 alkyl, monosubstituted or bisubstituted or polysubstitued C2-C14 alkenyl, monosubstituted or bisubstituted or polysubstitued C6-C14 aryl, or monosubstituted or bisubstituted or polysubstitued 5 to 6 membered heterocyclic group, or monosubstituted or bisubstituted or polysubstitued fused ring group containing nitrogen heteroatom; Y represents hydrogen, monosubstituted or bisubstituted or polysubstitued C1-C16 alkyl, monosubstituted or bisubstituted or polysubstitued C6-C12 aryl, or monosubstituted or bisubstituted or polysubstitued 5 to 6 membered heterocyclic group, or monosubstituted or bisubstituted or polysubstitued fused ring group containing nitrogen heteroatom. The derivatives of the present invention have the functions of antiviral medicine.

Potential Antitumor Agents. 59. Structure-Activity Relationships for 2-Phenylbenzimidazole-4-carboxamides, a New Class of "Minimal" DNA-Intercalating Agents Which May Not Act via Topoisomerase II

A series of substituted 2-phenylbenzimidazole-4-carboxamides has been synthesized and evaluated for in vitro and in vivo antitumor activity.These compounds represent the logical conclusion to our search for "minimal" DNA-intercalating agents with the lowest possible DNA-binding constants.Such "2-1" tricyclic chromophores, of lower aromaticity than the structurally similar 2-phenylquinolines, have the lowest DNA binding affinity yet seen in the broad series of tricyclic carboxamide intercalating agents.Despite very low in vitro cytotoxicities, several of the compoundshad moderate levels of in vivo antileukemic effects.However, the most interesting aspect of their biological activity was the lack of cross-resistance shown to an amsacrine-resistant P388 cell line, suggesting that these compounds may not express their cytotoxicity via interaction with topoisomerase II.